Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

DYRK1A in Down syndrome: an oncogene or tumor suppressor?
Yehudit Birger, Shai Izraeli
Yehudit Birger, Shai Izraeli
Published February 22, 2012
Citation Information: J Clin Invest. 2012;122(3):807-810. https://doi.org/10.1172/JCI62372.
View: Text | PDF
Commentary

DYRK1A in Down syndrome: an oncogene or tumor suppressor?

  • Text
  • PDF
Abstract

Children with Down syndrome (DS) have a markedly increased risk of developing acute megakaryoblastic leukemia (AMKL) and acute lymphoblastic leukemia compared with that of children without DS. Despite recent breakthroughs, it is not clear which genes on chromosome 21, the chromosome that is trisomic in individuals with DS, cause this predisposition. In this issue of the JCI, Malinge et al. report their loss- and gain-of-function experiments in mouse and human cells that show that increased expression of the kinase encoded by the chromosome 21 gene DYRK1A suppresses the nuclear factor of activated T cells pathway and promotes AMKL. Interestingly, the same protein has been suggested to contribute to the reduced risk of epithelial cancers in adults with DS, leading to the possibility that it could be proleukemic in children and antitumorigenic in adults.

Authors

Yehudit Birger, Shai Izraeli

×

Total citations by year

Year: 2021 2019 2016 2014 2012 Total
Citations: 3 1 1 2 1 8
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (8)

Title and authors Publication Year
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
B Pucelik, A Barzowska, JM Dąbrowski, A Czarna
International journal of molecular sciences 2021
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
MF Lindberg, L Meijer
International journal of molecular sciences 2021
Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors -A Review
MP Osuna-Marco, M López-Barahona, B López-Ibor, ÁM Tejera
Frontiers in Genetics 2021
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair
SE Guard, ZC Poss, CC Ebmeier, M Pagratis, H Simpson, DJ Taatjes, WM Old
Scientific Reports 2019
Low risk of solid tumors in persons with Down syndrome
H Hasle, JM Friedman, JH Olsen, SA Rasmussen
Genetics in Medicine 2016
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis
P Fernández-Martínez, C Zahonero, P Sánchez-Gómez
Molecular & Cellular Oncology 2014
Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc
Q Liu, N Liu, S Zang, H Liu, P Wang, C Ji, X Sun
PloS one 2014
Tumorigenesis in Down's syndrome: big lessons from a small chromosome
D Nižetić, J Groet
Nature Reviews Cancer 2012

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts